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ORIGINAL RESEARCH
Comparison of Cardiovascular Risk 
Factors in European Population Cohorts 
for Predicting Atrial Fibrillation and Heart 
Failure, Their Subsequent Onset, and Death
Benedikt Schrage, MD; Bastiaan Geelhoed, PhD; Teemu J. Niiranen, MD, PhD; Francesco Gianfagna, MD, PhD; 
Julie K. K. Vishram-Nielsen, MD, PhD; Simona Costanzo, PhD; Stefan Söderberg, MD, PhD;  
Francisco M. Ojeda, PhD; Erkki Vartiainen, MD, PhD; Maria Benedetta Donati, MD, PhD; Christina Magnussen, MD; 
Augusto Di Castelnuovo, PhD; Stephan Camen, MD; Jukka Kontto, MSc; Wolfgang Koenig, MD, PhD;  
Stefan Blankenberg, MD, PhD; Giovanni de Gaetano, MD, PhD; Allan Linneberg, MD, PhD;  
Torben Jørgensen, MD, PhD; Tanja Zeller, PhD; Kari Kuulasmaa, PhD; Hugh Tunstall-Pedoe, MD, PhD;  
Maria Hughes, PhD; Licia Iacoviello, MD, PhD; Veikko Salomaa, MD, PhD; Renate B. Schnabel , MD, MSc
BACKGROUND: Differences in risk factors for atrial fibrillation (AF) and heart failure (HF) are incompletely understood. Aim of this 
study was to understand whether risk factors and biomarkers show different associations with incident AF and HF and to 
investigate predictors of subsequent onset and mortality.
METHODS AND RESULTS: In N=58 693 individuals free of AF/HF from 5 population- based European cohorts, Cox regressions 
were used to find predictors for AF, HF, subsequent onset, and mortality. Differences between associations were estimated 
using bootstrapping. Median follow- up time was 13.8 years, with a mortality of 15.7%. AF and HF occurred in 5.0% and 5.4% 
of the participants, respectively, with 1.8% showing subsequent onset. Age, male sex, myocardial infarction, body mass index, 
and NT- proBNP (N- terminal pro- B- type natriuretic peptide) showed similar associations with both diseases. Antihypertensive 
medication and smoking were stronger predictors of HF than AF. Cholesterol, diabetes mellitus, and hsCRP (high- sensitivity 
C- reactive protein) were associated with HF, but not with AF. No variable was exclusively associated with AF. Population- 
attributable risks were higher for HF (75.6%) than for AF (30.9%). Age, male sex, body mass index, diabetes mellitus, and NT- 
proBNP were associated with subsequent onset, which was associated with the highest all- cause mortality risk.
CONCLUSIONS: Common risk factors and biomarkers showed different associations with AF and HF, and explained a higher 
proportion of HF than AF risk. As the subsequent onset of both diseases was strongly associated with mortality, prevention 
needs to be rigorously addressed and remains challenging, as conventional risk factors explained only 31% of AF risk.
Key Words: atrial fibrillation ■ biomarkers ■ heart failure ■ population ■ risk factors
Atrial fibrillation (AF) and heart failure (HF) are in-creasingly prevalent cardiovascular diseases. They frequently occur together or complicate 
each other. In permanent AF, the coprevalence of HF 
accounts for >50% of the cases.1 In individuals with 
HF, AF is observed in >40%.2 Both diseases are more 
frequently observed in older patients, and outcome 
seems to be worse if AF and HF coincide.3,4
AF and HF share common pathophysiological 
features as the atria and ventricles are interrelated 
Correspondence to: Renate B. Schnabel, MD, PhD, University Heart Center Hamburg-Eppendorf, Martinistrasse 52, 20246 Hamburg, Germany. E-mail: 
r.schnabel@uke.de
Supplementary Materials for this article are available at https://www.ahajo urnals.org/doi/suppl/ 10.1161/JAHA.119.015218
For Sources of Funding and Disclosures, see page 9.
© 2020 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley.  This is an open access article under the terms of the Creative 
Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use 
is non- commercial and no modifications or adaptations are made. 
JAHA is available at: www.ahajournals.org/journal/jaha
D
ow
nloaded from
 http://ahajournals.org by on June 8, 2020
J Am Heart Assoc. 2020;9:e015218. DOI: 10.1161/JAHA.119.015218 2
Schrage et al AF and HF in the General Population
mechanically, structurally, and electrically. For exam-
ple, increased end- diastolic left ventricular pressure 
in HF adversely affects atrial hemodynamics and may 
lead to AF.5 On the other hand, irregular atrioventricular 
conduction, in particular high heart rates, can induce 
left ventricular remodeling and, ultimately, HF.6
Similar conventional cardiovascular risk factors 
have been reported to be associated with incident AF 
and HF, such as age, arterial hypertension, smoking, 
and obesity. Many of the shared risk factors can be 
easily evaluated in the primary care setting.7–10
Biomarkers are another important tool for risk 
assessment. NT- proBNP (N- terminal pro- B- type 
natriuretic peptide) is widely used in this setting. It 
reflects cardiac stress, including end- diastolic left 
ventricular pressure. This constitutes a pathophysi-
ological link between AF and HF. It has been shown 
that NT- proBNP has a strong predictive value for 
both diseases in the general population.11,12 In ad-
dition, hsCRP (high- sensitivity C- reactive protein) is 
widely used for cardiovascular risk assessment, as 
population- based studies have shown strong asso-
ciations with cardiovascular and all- cause mortality 
events.13
Although the association of cardiovascular risk 
factors with incident AF and HF has been shown 
in different studies, no direct comparison of the di-
rection and strength of these associations has been 
performed across populations with differing levels 
of absolute HF and AF risk. In addition, biomarkers 
commonly used in cardiovascular medicine, such 
as NT- proBNP and hsCRP, have not been com-
pared in their predictive ability for both diseases.11,12 
Therefore, we systematically evaluated the direction 
and strength of the association of common cardio-
vascular risk factors and circulating biomarkers with 
the long- term incidence of AF and HF as well as with 
subsequent disease onset and mortality in European 
population- based cohorts.
METHODS
The data supporting the findings presented in 
this study are available from the Biomarker for 
Cardiovascular Risk Assessment in Europe con-
sortium (http://www.bioma rcare.eu) on reasonable 
request.
Study Sample
This study is based on the Monica Risk, Genetics, 
Archiving, and Monograph/Biomarker for Cardiovas-
cular Risk Assessment in Europe consortium. This 
consortium provides harmonization of risk factors, bio-
marker measurements, and end points from European 
population- based cohort studies.14 Information on AF 
and HF status at baseline and follow- up was available in 
59 913 participants from 5 cohort studies (DanMONICA, 
FINRISK, Moli- sani, Northern Sweden, and Scottish 
Heart Health Extended Cohort). Individuals with self- 
reported and/or physician- diagnosed history of AF or 
HF and/or prior International Classification of Diseases, 
Tenth Revision (ICD-10), coding for AF or HF at base-
line were excluded from this analysis (N=1220). A total 
of 58 693 individuals were included into the analysis. 
Details on the enrollment and follow- up procedures for 
each study separately are provided in Data S1 (Chapter 
1–5).
Risk Factors and Follow- Up
Risk factor information was collected at the baseline 
visit. Body mass index (BMI), systolic blood pres-
sure, heart rate, and total cholesterol were measured 
locally according to the World Health Organization 
CLINICAL PERSPECTIVE
What Is New?
• Atrial fibrillation and heart failure have distinct 
risk profiles, as they show different associations 
with common cardiovascular risk factors.
• Common cardiovascular risk factors explain a 
higher proportion of the risk of incident heart 
failure compared with atrial fibrillation.
• Although both diseases increase mortality risk, 
co-occurrence of both diseases carries the 
strongest association with mortality.
What Are the Clinical Implications?
• Modifiable risk factors should be targeted rigor-
ously at the population level to reduce the risk 
of incident atrial fibrillation and heart failure, in 
particular in individuals in whom one disease 
has already occurred.
• In particular, overweight/obesity should be ad-
dressed as this explains the highest proportion 
of modifiable attributable risk for both diseases.
Nonstandard Abbreviations and Acronyms
AF atrial fibrillation
BMI body mass index
HF heart failure
HR hazard ratio
hsCRP high- sensitivity C- reactive protein
IQR interquartile range
NT- proB  NPN- terminal pro- B- type natriuretic 
peptide
PAR population- attributable risk
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Multinational Monitoring of Trends and Determinants 
in Cardiovascular Disease (MONICA) protocol (https:// 
thl.fi/publi catio ns/monic a/manua l/index.htm). Obesity 
was defined as BMI ≥30 kg/m2. Information on diabe-
tes mellitus status, antihypertensive medication use, 
history of cardiovascular diseases, smoking, and av-
erage daily consumption of alcohol was obtained by 
self- report and collected locally in the study centers. All 
data from the cohort studies were harmonized in the 
Monica Risk, Genetics, Archiving, and Monograph pro-
ject.15 Creatinine was centrally measured from stored 
blood samples, and glomerular filtration rate was esti-
mated using the Chronic Kidney Disease Epidemiology 
Collaboration formula with creatinine.16 Data on miss-
ing values are displayed in Table S1.
AF and HF diagnoses were based on self- reported 
history of AF/HF and/or national hospital discharge 
registry data and/or data on ambulatory visits to spe-
cialized clinics. In addition, cause of death registry data 
were screened for incident AF and HF as comorbidities 
of individuals who died from other causes (https://thl.
fi/publi catio ns/morga m/cohor ts/index.html). Mortality 
data were derived from central death registries. The 
periods of baseline examinations of the cohorts varied 
between 1982 and 2010. The last follow- up was be-
tween 2010 and 2011 in the different cohorts (detailed 
information by study cohort are provided in Data S1, 
Chapter 1–5).
All participating cohort studies were approved by 
local ethics committees and institutional review boards; 
and all obtained informed consent from participants.
Biomarker Measurement
Biomarker measurements were performed from stored 
blood samples. hsCRP was measured by latex immu-
noassay (Abbott, Architect c8000) in 95% of the in-
dividuals, with intra- assay and interassay coefficients 
of variation of 0.93 and 0.83, respectively. NT- proBNP 
was measured on the ELECSYS 2010 platform using 
an electrochemiluminescence immunoassay (Roche 
Diagnostics) in 72.8% of the individuals. The analytical 
range is given as 5 to 35 000 pg/mL. Intra- assay and 
interassay coefficients of variation were 2.58 and 1.38, 
respectively.
Statistical Analysis
Binary variables are given as absolute and relative fre-
quencies, and continuous variables are given as me-
dian (25th, 75th percentile).
Heart rate was excluded from the analyses be-
cause it was only available in 2 cohorts (FINRISK and 
Moli- sani).
Univariable and multivariable- adjusted Cox propor-
tional hazard regressions with incident AF, incident HF, 
subsequent incident AF and HF, and mortality as end 
points were performed, using time since baseline as 
time scale. For the analysis of subsequent incident AF 
and HF, the end point was the first co- occurrence of 
both diseases and time to event was the time from 
baseline to this moment. When incident AF, incident 
HF, and/or subsequent incident AF and HF were co-
variates, they were included as time- dependent covari-
ates. Variable selection in the multivariable regression 
analysis was based on stepwise regression, using only 
variables that in corresponding univariate Cox propor-
tional hazards regression had a hazard ratio (HR) with 
P<0.1, with backwards elimination of the least signifi-
cant variable, when the P value of its HR exceeds 0.05 
during a regression step. Regression steps were re-
peated until no more variables were eliminated. All vari-
ables from Table 1 were included into the regression 
analysis. C- statistics of the fitted Cox models were 
calculated using the summary.coxph function from the 
Survival package in R.
To be able to compare the models with incident 
AF and HF, these models must contain the same vari-
ables, but with reversed roles of incident AF and HF. 
This was ensured by parallelizing the stepwise regres-
sions in the following way: the covariates incident AF 
and HF were treated as if they were the same vari-
able, but in the model with incident AF as end point 
the covariate incident HF was used and vice versa in 
Table 1. Baseline Characteristics of the Total Study 
Cohort
Characteristic
Study Population 
(N=58 693)
Age, y 50.5 (41.4, 59.2)
Sex (men) 28 920 (49.3)
Body mass index, kg/m2 26.1 (23.4, 29.2)
Total serum cholesterol, mmol/L 5.8 (5.0, 6.6)
Average daily consumption of alcohol, g 5.0 (0, 15.0)
Systolic blood pressure, mm Hg 131 (118, 145)
Heart rate, bpm 67.0 (60.0, 74.0)
Antihypertensive medication 8570 (14.8)
Smoking 16 611 (28.4)
Prevalent diabetes mellitus 2274 (3.9)
Prevalent myocardial infarction 1536 (2.6)
Prevalent stroke 731 (1.3)
NT- proBNP, pg/mL 48 (26, 89)
hsCRP, mg/L 1.3 (0.6, 2.8)
Estimated glomerular filtration rate, mL/
min per 1.73 m2
97.1 (85.8, 106.5)
Baseline characteristics of the pooled study cohort. Continuous variables 
are presented as median (25th, 75th percentile), and binary variables are 
presented as absolute and relative frequencies. Glomerular filtration rate was 
estimated using the Chronic Kidney Disease Epidemiology Collaboration 
formula with creatinine.16 All shown variables were used for the analyses. 
Bpm indicates beats per minute; hsCRP, high- sensitivity C- reactive protein; 
and NT- proBNP, N- terminal pro- B- type natriuretic peptide.
D
ow
nloaded from
 http://ahajournals.org by on June 8, 2020
J Am Heart Assoc. 2020;9:e015218. DOI: 10.1161/JAHA.119.015218 4
Schrage et al AF and HF in the General Population
the model with incident HF as end point the covariate 
incident AF was used. Then, the initially included vari-
ables were those that had a P value <0.1 in either the 
univariable analysis for AF or the univariable analysis 
for HF. During each regression step, each variable has 
2 P values (one from the incident AF model and one 
from the incident HF model) and the variable with the 
largest minimum of both was eliminated when both P 
values >0.05. All Cox proportional hazards regressions 
were adjusted for age, sex, and study area. To avoid 
nonlinearity in all multivariable Cox proportional haz-
ards models, the statistical significance of all possible 
second- order (self [ie, quadratic] and nonself) interac-
tions of the variables in the model was assessed and 
an interaction was included as additional covariate if its 
Bonferroni- corrected P value was <0.05. Interactions 
with time since baseline were added when needed to 
avoid violations of the proportional hazard’s assump-
tion, which were identified using the R function cox.
zph. To add these interactions with time to the model, 
the analysis data set was further segmented into time 
intervals of 1 year and the time variable was updated 
yearly, starting with time=0 during the first time inter-
val. When included in an interaction, numeric variables 
were centered on their mean. Two- sided P values for 
differences between HRs and CIs were estimated 
using bootstrapping with 1000 replications. The con-
structed bootstrap populations were formed by repli-
cating each person 10 times. Bootstrap samples were 
then drawn from this bootstrap population using sim-
ple random sampling. Symmetric 95% bootstrap CIs 
were estimated as m−e and m+e, where m=the mean 
of the bootstrap estimates and e=the 95% percentile of 
absolute deviations of bootstrap estimates from m.17,18
Population- attributable risks (PARs) were calcu-
lated using the fully adjusted estimated HRs to re-
place the relative risk ratios in the original formula 
for PAR. Hence, the PAR of each risk category of 
each risk factor was calculated using pd×(HR−1)/HR, 
where pd is the proportion of those in the risk cat-
egory among the cases (incident AF or HF) during 
a 5- year follow- up. The total PAR of a risk factor is 
the sum of all PARs of its risk categories. For each 
PAR, bootstrapping with 1000 repetitions was used 
for estimating its associated 95% CI, the P values 
for the differences between PARs, and associated 
95% CIs. For the calculation of PARs, continuous 
variables were categorized as follows: BMI using 3 
categories (<25, 25–<30, and ≥30  kg/m2) and total 
cholesterol using 2 categories based on the cutoff 
value 5.2 mmol/L (as it is an accepted cutoff point 
for elevated total cholesterol in the general popula-
tion; eg, this cutoff point is used in the Framingham 
risk score). The category containing the lowest val-
ues was taken as reference level during the PAR 
calculation.
The Bonferroni correction was used to account for 
multiple testing in the presented models (eg, dividing 
the prespecified α of 0.05 by the number of indepen-
dent tests).
Analyses were performed with R v.3.5.1.19
RESULTS
Baseline Characteristics
The baseline characteristics of study participants are 
shown in Table 1 for the overall cohort and in Tables 
S2 through S6 for each individual cohort study. The 
median age of the study population was 50.5  years 
(interquartile range [IQR], 41.4–59.2 years), and 49.3% 
of the individuals were men. During a median follow-
 up of 13.8 years (IQR, 4.5–21.9 years), 2959 (5.0%) in-
dividuals were diagnosed with incident AF and 3141 
(5.4%) individuals were diagnosed with incident HF. 
Median time to the first AF or HF event was 12.7 (IQR, 
7.1–18.1) and 11.1  (IQR, 5.6–16.6) years, respectively. 
Subsequent disease onset was observed in 1028 
(1.8% of the total sample) individuals.
Different Associations of Cardiovascular 
Risk Factors and Biomarkers With AF and 
HF
Multivariable- adjusted Cox regression analysis indi-
cated different associations of common cardiovascu-
lar risk factors and circulating biomarkers with incident 
AF and HF (Table 2): Age, male sex, prevalent myocar-
dial infarction, and log10(NT- proBNP) showed a similar 
strength of association with incident AF and HF. BMI, 
antihypertensive medication, and smoking were ob-
served to be stronger predictors of incident HF than 
incident AF. Total serum cholesterol, prevalent diabe-
tes mellitus, and hsCRP were associated with an in-
creased risk of incident HF; however, they did not show 
a statistically significant association with incident AF. 
No variable was exclusively associated with incident 
AF. After Bonferroni correction, AF and HF no longer 
differed in their strength of association with BMI.
The C- statistic for the model for incident AF was 
0.846, whereas the C- statistic for the model for inci-
dent HF was 0.87.
Interim incidence of AF was associated with an in-
creased risk of subsequent incident HF and vice versa 
(HR, 6.84 [95% CI, 4.89–9.59] [P<0.001]; and HR, 7.05 
[95% CI, 4.89–10.16] [P<0.001]). Sex- stratified analyses 
are provided in Tables S7 and S8.
Predictors of Subsequent Disease Onset
Age, male sex, BMI, total serum cholesterol, prevalent 
diabetes mellitus, and log10(NT- proBNP) were signifi-
cantly associated with an increased risk of subsequent 
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new onset of both diseases (Table 3). Evaluating the 
subsequent disease onset on the basis of duration be-
tween each diagnosis (within 30 days versus AF before 
HF outside of 30  days versus HF before AF outside 
of 30 days) did not lead to relevant changes of these 
associations. After Bonferroni correction, total serum 
cholesterol was no longer significantly associated with 
subsequent disease onset.
The C- statistic for the model for subsequent dis-
ease onset was 0.91.
Sex- stratified analyses are provided in Tables S9 
and S10.
Predictors of All- Cause Mortality
During the follow- up, 9221 (15.7%) individuals died with 
a median time to death of 12.7 (IQR, 7.2–18.1) years. 
The results of the multivariable- adjusted Cox regres-
sion analysis for the end point of all- cause mortality 
are shown in Figure 1. The incidence of either disease 
was significantly associated with all- cause mortality, 
whereas this association was stronger for incident HF 
than incident AF (AF: HR, 2.29 [95% CI, 2.04–2.58] 
[P<0.001]; and HF: HR, 10.95 [95% CI, 8.92–13.44] 
[P<0.001]). Subsequent new onset of both diseases 
further increased mortality risk (HR, 13.10 [95% CI, 
10.13–16.93] [P<0.001] compared with individuals 
without AF and HF). All associations remained statisti-
cally significant after Bonferroni correction.
The C- statistic for the model for all- cause mortality 
was 0.82.
Population- Attributable Risks
PAR for 5- year incidence of AF or HF based on com-
mon cardiovascular risk factors and circulating bio-
markers is shown in Figure 2 (Table S11). The overall 
PAR of common cardiovascular risk factors was 
Table 2. Association of Risk Factors and Biomarker With Incident Diseases
Variable Disease
Hazard Ratio  
(95% CI) P Value
Hazard Ratio Difference 
(95% CI) P Value
Age (per 5- y increase) AF 1.59 (1.52/1.67) <0.001 0.00 (−0.10/0.10) 0.99
HF 1.59 (1.52/1.67) <0.001
Sex (men) AF 2.92 (2.48/3.41) <0.001 0.58 (−0.01/1.17) 0.05
HF 2.34 (1.98/2.75) <0.001
Body mass index (per 5- kg/m2 
increase)
AF 1.31 (1.25/1.38) <0.001 −0.11 (−0.19/−0.02) 0.02
HF 1.42 (1.35/1.49) <0.001
Total serum cholesterol (per 
1- mmol/L increase)
AF 1.01 (0.97/1.05) 0.55 −0.06 (−0.12/−0.01) 0.03
HF 1.07 (1.03/1.12) <0.001
Antihypertensive medication AF 1.24 (1.09/1.39) <0.001 −0.29 (−0.50/−0.08) <0.001
HF 1.52 (1.35/1.71) <0.001
Smoking AF 1.19 (1.06/1.32) <0.001 −0.92 (−1.15/−0.69) <0.001
HF 2.10 (1.90/2.31) <0.001
Prevalent diabetes mellitus AF 1.14 (0.68/1.60) 0.56 −2.19 (−3.14/−1.25) <0.001
HF 3.33 (2.50/4.17) <0.001
Prevalent myocardial infarction AF 1.56 (1.16/1.97) <0.001 −0.25 (−0.83/0.33) 0.39
HF 1.81 (1.44/2.20) <0.001
Log10(NT- proBNP) (per 0.3 increase) AF 1.54 (1.45/1.63) <0.001 0.07 (−0.05/0.19) 0.23
HF 1.46 (1.38/1.55) <0.001
hsCRP (per 5- mg/L increase) AF 1.00 (0.93/1.06) 0.91 −0.13 (−0.20/−0.05) <0.001
HF 1.13 (1.08/1.17) <0.001
Estimated glomerular filtration rate 
(per 20- mL/min per 1.73 m2 increase)
AF 1.04 (0.95/1.14) 0.38 0.10 (−0.01/0.22) 0.09
HF 0.94 (0.86/1.03) 0.16
Incident AF during follow- up HF 6.84 (4.45/9.28) <0.001
Incident HF during follow- up AF 7.05 (4.43/9.80) <0.001
The following variables were also fitted into, but then dropped from, the Cox regression model: cholesterol- lowering medication, daily consumption of 
alcohol, systolic blood pressure, heart rate, and prevalent stroke. In addition, cohort stratification was adjusted for. After Bonferroni correction to account for 
multiple testing, a P value threshold of <0.002 was used. Additional interaction terms were added to improve model fit: sex and age, log10(NT- proBNP) and 
prevalent myocardial infarction, AF/HF and age, AF/HF and log10(NT- proBNP), diabetes mellitus and age, diabetes mellitus and cholesterol, log10(NT- proBNP) 
and age, log10(NT- proBNP) and log10(NT- proBNP), CRP and age, glomerular filtration rate and sex, AF/HF and antihypertensive medication, FINRISK and sex, 
age and time, CRP and time, northern Sweden and time, and DanMONICA and time. P values and CIs estimated by bootstrapping with 1000 repetitions. AF 
indicates atrial fibrillation; HF, heart failure; hsCRP, high- sensitivity C- reactive protein; and NT- proBNP, N- terminal pro- B- type natriuretic peptide.
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30.9% for incident AF and 75.6% for incident HF. After 
Bonferroni correction, the PAR of BMI for AF and HF 
was no longer significantly different, whereas the dif-
ferences between the PAR of other cardiovascular risk 
factors for AF and HF remained statistically significant.
DISCUSSION
In this pooled analysis of European population- based 
cohorts, incident AF and HF showed different asso-
ciations with common cardiovascular risk factors. 
The association was generally stronger with incident 
HF, and no risk factor was exclusively associated 
with incident AF. Obesity demonstrated the highest 
attributable risk for both diseases. In general, PAR 
was higher for incident HF, with >70% of the PAR 
explained for HF. Among the tested biomarkers, NT- 
proBNP showed a strong association with both inci-
dent diseases. The incidence of both diseases was 
predictive of mortality. The highest risk of all- cause 
death was observed with subsequent onset of both 
diseases. The present study extends prior knowl-
edge by showing that the associations of common 
cardiovascular risk factors and incident AF and HF 
appear to differ in strength.
Association of Common Cardiovascular 
Risk Factors With Incident AF and HF
Approximately 5% of individuals in our study spanning a 
large age range developed AF or HF, with ≈2% showing 
subsequent onset of both diseases. Common cardio-
vascular risk factors showed different associations with 
Table 3. HRs for Subsequent Disease Onset of Incident AF 
and Incident HF
Variable HR (95% CI) P Value
Age (per 5- y increase) 1.80 (1.66/1.96) <0.001
Sex (men) 4.41 (3.06/6.36) <0.001
Body mass index (per 5- kg/
m2 increase)
1.61 (1.49/1.73) <0.001
Total serum cholesterol (per 
1- mmol/L increase)
1.09 (1.02/1.16) 0.01
Prevalent diabetes mellitus 1.66 (1.27/2.17) <0.001
Log10(NT- proBNP) (per 0.3 
increase)
1.96 (1.85/2.08) <0.001
The following variables were also fitted into, but then dropped from, the 
Cox regression model: cholesterol- lowering medication, daily consumption 
of alcohol, systolic blood pressure, heart rate, antihypertensive medication, 
smoking status, prevalent myocardial infarction, prevalent stroke, hsCRP 
(high- sensitivity C- reactive protein), and estimated glomerular filtration rate. 
Adjustment for cohort stratification was implemented. After Bonferroni 
correction to account for multiple testing, a P value threshold of <0.0022 was 
used. Additional interaction terms were added to improve model fit: age and sex 
and log10(NT- proBNP) and time. AF indicates atrial fibrillation; HF, heart failure; 
HR, hazard ratio; and NT- proBNP, N- terminal pro- B- type natriuretic peptide.
Figure 1. Hazard ratios of cardiovascular risk factors, circulating biomarkers, incident diseases, and subsequent disease 
onset for all- cause mortality. 
The following variables were fitted into the Cox regression model as independent predictors: age, sex, body mass index, total serum 
cholesterol, cholesterol- lowering medication, daily consumption of alcohol, systolic blood pressure, heart rate, antihypertensive 
medication, smoking status, diabetes mellitus, prevalent myocardial infarction, prevalent stroke, log10(NT- proBNP [N- terminal pro- B- type 
natriuretic peptide]), hsCRP (high- sensitivity C- reactive protein), estimated glomerular filtration rate, incident atrial fibrillation (AF), incident 
heart failure (HF), subsequent disease onset, and cohort stratification. After Bonferroni correction to account for multiple testing, a P 
value threshold of <0.0021 was used. Additional interaction terms were added to improve model fit: age and sex, systolic blood pressure 
and age, diabetes mellitus and age, log10(NT- proBNP) and age, log10(NT- proBNP) and log10(NT- proBNP), hsCRP and age, hsCRP and 
hsCRP, HF and age, HF and sex, sequential disease onset and sex, FINRISK and AF, age and time, and northern Sweden and time.
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both incident diseases in multivariable- adjusted Cox 
regression models. Only 4 cardiovascular risk factors 
revealed comparable associations with both diseases, 
whereas no variable was exclusively associated with in-
cident AF. The directions of the associations were in line 
with previous reports.12,20,21 The association of diabetes 
mellitus with AF has remained inconsistent, whereas a 
strong association with incident HF is known.7,22
A possible explanation for these findings could be that 
risk factors contribute specifically to distinct pathophysio-
logical pathways. This results in a different impact on the 
genesis of each disease. As the strength of association 
appeared to be generally higher for incident HF than for 
incident AF, it can be assumed that classic risk factor re-
lated mechanisms have a greater impact on HF than on 
AF. Misclassification of events, especially in the case of 
asymptomatic AF, could also have weakened the asso-
ciations and may help explain the observed differences.
The strength of association translated into greater 
attributable risks of each individual risk factor for HF 
than for AF. Consequently, targeting the modifiable 
risk factors obesity, cholesterol, arterial hypertension, 
smoking, and diabetes mellitus seems to be associ-
ated with a greater risk reduction for HF than for AF 
(75.6% versus 30.9%). Among all evaluated modifiable 
risk factors, higher BMI revealed the highest attribut-
able risk for both incident diseases. The presented 
data indicate that 19.9% of AF cases and 28.0% of HF 
cases in this population could be attributed to a BMI 
of ≥25 kg/m2. Our findings are consistent with previous 
studies reporting a strong association of overweight/
obesity with incident AF and HF.23,24 Consequently, 
overweight/obesity should be rigorously targeted by 
prevention strategies for both diseases.
Circulating Biomarkers
Among circulating biomarkers, NT- proBNP showed 
a strong association with both diseases. This ob-
servation is in line with previous studies consist-
ently reporting a relationship between NT- proBNP 
and AF and HF.11,25–27 NT- proBNP is closely related 
to left ventricular pressure and myocardial stretch.28 
Both are increased as a consequence of HF and a 
pathogenetic factor for AF.29 In the general popula-
tion, elevated NT- proBNP might thus serve as an 
indicator of cardiac stress, which is related to both, 
subclinical AF, or HF. It may constitute an early warn-
ing sign of patients at high risk of disease manifes-
tation. Although direct targeting of NT- proBNP is a 
theoretical approach, this conveys the importance of 
reducing left ventricular filling pressures (eg, via treat-
ment of arterial hypertension) to decrease the risk of 
subsequent AF and HF.
hsCRP showed a strong association with incident HF, 
but not with incident AF. Although previous studies have 
reported an association of hsCRP and incident AF, the 
association has remained weak and did not improve risk 
scores based on common cardiovascular risk factors.11 
Similarly, in the current analysis, which included several 
common cardiovascular risk factors in the multivariable 
analysis, hsCRP did not reach statistical significance. On 
Figure  2. Bar chart showing the population- attributable risks (PARs) for 5- year incidence for 
atrial fibrillation (AF) or heart failure (HF) on common cardiovascular risk factors. 
Error bars represent 95% CIs. P values and CIs estimated by bootstrapping with 1000 repetitions. 
Variables with a statistically significant difference after Bonferroni correction (P<0.01) of the PAR between 
both diseases are marked with an asterisk (*). 
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the basis of these findings, it can be speculated that in-
flammation is only a minor driver for AF.
For HF, inflammatory pathways are known to be in-
volved in its pathogenesis, whereas the exact direction 
of the relationship is incompletely understood.30,31 The 
strong association of hsCRP with incident HF indicates 
a potential role of inflammation- modulating therapies 
for prevention at the population level.
Risk of Subsequent Disease Onset and 
All- Cause Mortality
Although incident HF was associated with a higher risk 
of all- cause death than AF, the highest risk was ob-
served with subsequent disease onset. Either disease 
showed a high risk for subsequent disease onset. The 
direction and strength of these associations did not differ 
if accounting for timing of disease onset. Reports from 
diseased cohorts show similar increases in disease or 
premature mortality outcomes with subsequent onset 
of both diseases.3 The subsequent disease onset may 
be an indicator of disease deterioration. This would ex-
plain the substantially higher mortality risk. Modifiable 
clinical risk factors, in particular BMI and diabetes mel-
litus, were observed to be significantly associated with 
subsequent disease onset. Other variables (eg, antihy-
pertensive medication or smoking) were not related to 
subsequent disease incidence despite their associa-
tion with both diseases individually. However, medica-
tion at baseline may have been modified after disease 
onset, and smoking cessation often is a reaction to a 
cardiac event and baseline smoking status may thus 
have lost its association.32
Although the exact nature of this finding cannot be 
explained on the basis of the present analysis, the in-
creased risk of subsequent disease onset highlights 
the importance of preventive therapies in individuals 
with recent onset of either disease.
Future Implications
In this analysis, classic modifiable risk factors sub-
stantially contributed to the risk of incident AF and HF 
(Figure 3). As both diseases are associated with a higher 
risk of mortality, modifiable risk factors should be rigor-
ously targeted in the general population and patients 
with incident disease. Measures to reduce the risk of 
either disease should particularly focus on overweight/
obesity, as overweight/obesity explained the highest 
proportion of risk for AF and HF. Furthermore, preven-
tion of diabetes mellitus, smoking, and arterial hyper-
tension seems to provide merit in reducing the risk of 
incident HF, but only to a minor part in reducing the risk 
of incident AF. Preventive measures should also include 
individuals with either disease, as subsequent disease 
onset was associated with the highest mortality risk.
The strong association of elevated NT- proBNP 
with both incident diseases highlights a potential area 
for future research. Reduction of left ventricular filling 
pressures, either via treatment of causative diseases 
(eg, arterial hypertension) or as a direct drug target, 
could be a promising measure at the general popu-
lation level to decrease the risk of incident AF or HF. 
Anti- inflammatory interventions might have merits as 
preventive measures for HF because of the strong as-
sociation of hsCRP with incident HF.
Limitations
Information on distinct AF and HF characteristics dur-
ing the follow- up cannot be provided, as data on these 
outcomes were derived from ICD-10–based healthcare 
registries. In addition, these secondary data might have 
Figure 3. Common cardiovascular risk factors and biomarkers 
show different associations with incident atrial fibrillation (AF) 
and heart failure (HF), their subsequent onset, and death.
BMI indicates body mass index; hsCRP, high- sensitivity C- 
reactive protein; MI, prevalent myocardial infarction; and NT- 
proBNP, N- terminal pro- B- type natriuretic peptide.
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varying quality, which could have impacted the results. 
Some variables, including baseline AF and HF, were self- 
reported. Thus, misclassification may have occurred. 
Furthermore, asymptomatic cases might have been 
missed more easily for AF than for HF. A significant bias 
caused by misclassification would have led to a more 
homogeneous shift of the associations when comparing 
AF and HF. However, our results predominantly revealed 
heterogeneous differences in the associations, which 
are less likely to be explained by mere misclassification. 
There are no available data on the treatment after inci-
dent manifestation of either disease, which might have 
influenced the results. Consequently, the present finding 
cannot be used to draw a causal relationship between 
both diseases and their relation to mortality.
CONCLUSIONS
Although AF and HF share pathophysiological similari-
ties and frequently coexist, our data reveal distinct risk 
profiles that may be related to specific pathophysiolog-
ical aspects of both diseases. Overall, classic risk fac-
tors explain a higher proportion of risk of HF compared 
with AF. Both disease entities significantly increase the 
risk of all- cause mortality, most strongly if both dis-
eases occur together. Consequently, prevention of 
AF and HF, in particular in individuals in whom one 
disease has occurred already, needs to be addressed 
rigorously. Modifiable traditional risk factors, such as 
overweight and obesity, hypertension, and diabetes 
mellitus, provide opportunities for interventions.
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Overview and description of the included BiomarCaRE cohorts 
 
Chapter 1. DanMONICA 
The DanMONICA cohorts from the Research Center for Prevention and Health are three prospective 
population based cohorts from 11 municipalities from the western part of the suburbs of Copenhagen, 
Denmark. Simple random sampling, stratified by sex and year of birth, was based on the national 
population register. Cohort 1 and 3 consists of men and women aged 30-70 years and cohort 2 consists 
of men and women aged 30-60 years. Cohort 1 was collected in 1982-1984. Cohort 2 was examined in 
1986-1987 and cohort 3 was examined in 1991-1992. Follow-up was achieved through linkage to the 
National Cause of Death Register and National Hospital Discharge Register, with endpoint diagnosis 
based on MORGAM criteria. Follow-up for the cohorts 1, 2, and 3 was completed to December 31st, 
2010.  
Information on prevalent (if recorded before the examination date) and incident (if recorded during the 
follow-up period) atrial fibrillation was obtained using the ICD-8 codes 427.93 or 427.94 or the ICD-10 
code I48. Information on prevalent (if recorded before the examination date) and incident (if recorded 
during the follow-up period) heart failure was obtained using the ICD-8 codes 427.0, 427.1 or 428 or the 
ICD-10 codes I11.0, I13.0, I13.2 or I50. 
http://www.thl.fi/publications/morgam/cohorts/full/denmark/den-gloa.htm 
 
Chapter 2. FINRISK 
The FINRISK study is a series of population-based cardiovascular risk factor surveys carried out every 
five years in five districts of Finland, including North Karelia (in 1982-2002), Northern Savo (former 
Kuopio, in 1982-2002), Southwestern Finland (in 1982-2002), Oulu Province (in 1997-2002) and the 
region of Helsinki and Vantaa (in 1992-2002). For the present analysis, the study from 1997 was used, 
as biomarker measurements and variable harmonization were available for this study. A stratified 
random sample (stratification by sex and 10-year age group) was drawn from the national population 
register; the age-range was 25-74 years. All individuals enrolled in the study received a physical 
examination, a self-administered questionnaire, and a blood sample was drawn. During follow-up, the 
National Hospital Discharge Register, the National Causes of Death Register and the National Drug 
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Reimbursement Register were used to identify endpoints. At the moment, the follow-up extends until 
December 31st, 2010. The cohort is divided in the eastern and the south-western FINRISK cohort 
Information on prevalent (if recorded before the examination date) and incident (if recorded during the 
follow-up period) atrial fibrillation was obtained using the ICD-8 code 427.92, the ICD-9 code 427.93 or 
the ICD-10 code I48. 
Persons hospitalized with any of the ICD-8 codes 427.00, 427.10, 428; or the ICD-9 codes 402.9B, 
414.8, 428; or the ICD-10 codes I50, I110, I130, I132 were considered having prevalent heart failure. 
Also, if a person had received ‘special reimbursements’ for heart failure medications, i.e., had the KELA 
code 201 (chronic heart failure - insufficientia cordis, incompensatio cordis chronica) before the 
examination date, or had purchased at least three times before the examination date drugs with ATC 
codes C03CA01 (furosemide) or C03EB01 (furosemide and potassium-sparing agents in combination) 
the person was considered having prevalent heart failure. Additionally, an affirmative answer to an 
option ‘Heart failure’ under the question ‘Have you during the last year had any of the following diseases 
confirmed or treated by a doctor?’ was considered as self-reported prevalent heart failure. Incident heart 
failure diagnosis was based on national hospital discharge registry data, including data on ambulatory 
visits to specialized hospitals, and cause of death registry data using the above described ICD codes 
and ATC codes. 
http://www.thl.fi/publications/morgam/cohorts/full/finland/fin-fina.htm 
 
Chapter 3. Moli-sani 
The cohort of the Moli-sani study was recruited in the Molise region in Italy from city hall registries using 
multistage sampling. First, townships were sampled in major areas by cluster sampling; then, within 
each township, participants aged 35 years or over were selected by simple random sampling. Exclusion 
criteria were pregnancy at the time of recruitment, lack of understanding (e.g. language difficulties), 
current multiple trauma or coma, or refusal to sign the informed consent. A total of 24325 men (47%) 
and women (53%) over the age of 35 years were examined at baseline from 2005 to 2010. Participation 
rate was 70%. The cohort was followed-up for a median of 4.2 years (maximum 6.5 years) at December 
2011. Follow-up is achieved through record linkage to national mortality registries and hospital discharge 
registers, validation of cardiovascular events was achieved through hospital record linkage and doctors 
medical records using updated MORGAM criteria.  
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Information on prevalent atrial fibrillation was obtained via medical reports at the baseline visit or an 
affirmative answer to the question "Have you ever been diagnosed with atrial fibrillation?". The question 
was not asked during the first year of recruitment of participants to the cohort. Information on incident 
atrial fibrillation was obtained via hospital discharge records with the ICD-9 code 426.3. Information on 
prevalent heart failure was obtained via medical reports at the baseline visit or an affirmative answer to 
the question "Have you ever been diagnosed with heart failure?". Information on incident heart failure 
was obtained via linkage with hospital discharge forms, according to the ICD-9-CM code: 428 (“Heart 
failure”). Incidence was defined as the first occurrence of a hospitalization for heart failure.  
https://thl.fi/publications/morgam/cohorts/full/italy/ita-mola.htm#dprocedure 
 
Chapter 4. Northern Sweden:  
The Northern Sweden MONICA study covered the two northernmost counties of Sweden, i.e. Norrbotten 
and Västerbotten with altogether 510,000 inhabitants. Population surveys were performed in 1986, 
1990, 1994, 1999, 2004 and 2009, with altogether 10,517 unique participants. On the first two occasions, 
2,000 persons aged 25 to 64 years were randomly selected from the national population registry per 
survey, and in the last three surveys, the upper age limit was extended to 74 years and 2,500 individuals 
were invited per survey. A stratified randomized selection procedure by age and sex (250 persons in 
each sex/10-year age stratum) has been used. The participation rate was 69-81%. Detailed analyses of 
non-participants have been performed. In 1999, all people invited to any of the three previous population 
surveys were re-invited for repeated measurements to be collected. Incident cardiovascular events 
(myocardial infarction and stroke) occurring in the region between 1985 and 2010 and below the age of 
75 were collected and validated according to MONICA criteria by two event registers whose accuracy 
and validity have been tested against national registers. Follow-up is available for all cohorts until 
December 2011 for mortality, chronic heart failure and atrial fibrillation, using data from the National 
Swedish cause of death and in-patient care registers. 
Information on prevalent (if recorded before the examination date) and incident (if recorded during the 
follow-up period) atrial fibrillation was obtained using the following ICD codes: ICD-8-SV 42792, ICD-9-
SV 427D, ICD-10-SE I489 plus the Swedish modification A to F as fifth position differentiating between 
flutter and fibrillation, and paroxysmal or chronic flutter/fibrillation.  
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Information on prevalent (if recorded before the examination date) and incident (if recorded during the 
follow-up period) heart failure was obtained using the following ICD codes: ICD-8-SV 42700, ICD-9-SV 
428, ICD-10-SE I11.0, I50. 
http://www.thl.fi/publications/morgam/cohorts/full/sweden/swe-nswa.htm 
 
Chapter 5. Scottish Heart Health Extended Cohort  
This consists of two overlapping studies which share a common protocol and methods: the Scottish 
Heart Health Study randomly recruited men and women aged 40-59 across 22 Scottish districts in 1984-
1987; Scottish MONICA similarly recruited men and women aged 25-64 in Edinburgh and North 
Glasgow in 1986, and in North Glasgow again in 1989, 1992 (to 74), and in 1995 as part of the WHO 
MONICA Project. They are now combined as one cohort, although length of follow-up, currently to the 
end of 2009, inevitably varies in the different components (Edinburg, Glasgow and rest of Scotland). 
Follow up is achieved through flagging for death certificates at the National Health Service Death 
Register and through the Scottish Record Linkage scheme for deaths and hospital discharge records 
run by Information Services Scotland, which works on probability matching. These diagnoses are no 
longer validated from case notes now that endpoint numbers run into thousands as the cohort ages, but 
they are allocated to MORGAM categories.  
Information on prevalent (if recorded before the examination date) and incident (if recorded during the 
follow-up period) atrial fibrillation and heart failure was obtained from hospital admissions since 1981 
from record linkage as well as from death certificates. 
http://www.thl.fi/publications/morgam/cohorts/full/uk/unk-sco.htm 
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Table S1. Variables used for the regression analysis including percentages of missing values. 
 
 % missing 
N=58693 
Age  0 
Sex  0 
Body mass index  0.2 
Total serum cholesterol  0.4 
Average daily consumption of alcohol  3.5 
Systolic blood pressure 0 
Heart rate  57.8 
Antihypertensive medication  1.3 
Smoking  0.4 
Prevalent diabetes  0.1 
Prevalent myocardial infarction  0.4 
Prevalent stroke  0.4 
NT-proBNP  27.2 
High-sensitive C-reactive protein  5.0 
Estimated glomerular filtration rate 4.9 
 
Heart rate was only available in Moli-sani and Finrisk; NT-proBNP was not available in DanMONICA. 
NT-proBNP: N-terminal pro B-type natriuretic peptide. 
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Table S2. Baseline characteristics of the DanMONICA cohort. 
  Study population 
N=7629 
Age (years) 50.0 (39.9, 60.2) 
Sex (male) 3843 (50.4) 
Body mass index (kg/m2) 24.4 (22.1, 27.2) 
Total serum cholesterol (mmol/L) 5.8 (5.0, 6.6) 
Average daily consumption of alcohol (g) 8.0 (3.0, 18.0) 
Systolic blood pressure (mmHg) 122 (111, 134) 
Heart rate (bpm) Not available 
Antihypertensive medication No. (%) 506 (6.9%) 
Smoking No. (%) 3422 (44.9%) 
Prevalent diabetes No. (%) 176 (2.3) 
Prevalent myocardial infarction No. (%) 151 (2.0) 
Prevalent stroke No. (%) 84 (1.1) 
NT-proBNP (pg/mL) Not available 
High-sensitive C-reactive protein (mg/L) 1.2 (0.6, 2.8) 
Estimated glomerular filtration rate 
(ml/min/1.73 m2) 
98.6 (86.2, 109.5) 
 
Baseline characteristics of the pooled DanMONICA cohorts. Continuous variables are presented as 
median (25th, 75th percentile), binary variables as absolute and relative frequencies. Glomerular filtration 
rate was estimated using the CKD-EPI formula with creatinine [29]. NT-proBNP: N-terminal pro B-type 
natriuretic peptide.  
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Table S3. Baseline characteristics of the FINRISK cohort. 
  Study population 
N=8072 
Age (years) 47.7 (36.8, 59.0) 
Sex (male) 4011 (49.7%) 
Body mass index (kg/m2) 26.1 (23.5, 29.1) 
Total serum cholesterol (mmol/L) 5.4 (4.8, 6.2) 
Average daily consumption of alcohol (g) 3.0 (0.0, 11.0) 
Systolic blood pressure (mmHg) 133.0 (121.0, 148.0) 
Heart rate (bpm) 68.0 (62.0, 78.0) 
Antihypertensive medication No. (%) 965 (12.3%) 
Smoking No. (%) 1754 (22.1%) 
Prevalent diabetes No. (%) 414 (5.1%) 
Prevalent myocardial infarction No. (%) 242 (3.0%) 
Prevalent stroke No. (%) 185 (2.3%) 
NT-proBNP (pg/mL) 46.0 (24.2, 84.0) 
High-sensitive C-reactive protein (mg/L) 1.1 (0.5, 2.4) 
Estimated glomerular filtration rate 
(ml/min/1.73 m2) 
90.0 (77.9, 101.5) 
 
Baseline characteristics of the FINRISK study cohort. Continuous variables are presented as median 
(25th, 75th percentile), binary variables as absolute and relative frequencies. Glomerular filtration rate 
was estimated using the CKD-EPI formula with creatinine [29]. NT-proBNP: N-terminal pro B-type 
natriuretic peptide.  
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Table S4. Baseline characteristics of the Moli-sani cohort. 
  Study population 
N=16723 
Age (years) 53.9 (45.5, 63.2) 
Sex (male) 7962 (47.6) 
Body mass index (kg/m2) 27.5 (24.8, 30.8) 
Total serum cholesterol (mmol/l) 5.5 (4.8, 6.3) 
Average daily consumption of alcohol (g) 6 (0, 27) 
Systolic blood pressure (mmHg) 137 (125, 152) 
Heart rate (bpm) 66 (60, 73) 
Antihypertensive medication No. (%) 4647 (27.9) 
Smoking No. (%) 3422 (20.5) 
Prevalent diabetes No. (%) 1028 (6.2) 
Prevalent myocardial infarction No. (%) 313 (1.9) 
Prevalent stroke No. (%) 113 (0.7) 
NT-proBNP (pg/mL) 49.3 (26.5, 89.8) 
High-sensitive C-reactive protein (mg/L) 1.6 (0.8, 3.1) 
Estimated glomerular filtration rate 
(ml/min/1.73 m2) 
96.8 (87.7, 104.8) 
 
Baseline characteristics of the Moli-sani study cohort. Continuous variables are presented as median 
(25th, 75th percentile), binary variables as absolute and relative frequencies. Glomerular filtration rate 
was estimated using the CKD-EPI formula with creatinine [29]. NT-proBNP: N-terminal pro B-type 
natriuretic peptide. 
  
D
ow
nloaded from
 http://ahajournals.org by on June 8, 2020
Table S5. Baseline characteristics of the Northern Sweden cohort. 
  Study population 
N=10312 
Age (years) 48.5 (37.2, 59.5) 
Sex (male) 5063 (49.1) 
Body mass index (kg/m2) 26.2 (23.5, 29.6) 
Total serum cholesterol (mmol/l) 5.8 (5.0, 6.7) 
Average daily consumption of alcohol (g) 2 (0, 5) 
Systolic blood pressure (mmHg) 127 (115, 141) 
Heart rate (bpm) Not available 
Antihypertensive medication No. (%) 1266 (12.4) 
Smoking No. (%) 1883 (18.3) 
Prevalent diabetes No. (%) 382 (3.7) 
Prevalent myocardial infarction No. (%) 312 (3.0) 
Prevalent stroke No. (%) 194 (1.9) 
NT-proBNP (pg/mL) 43.0 (22.3, 81.4) 
High-sensitive C-reactive protein (mg/L) 1.0 (0.5, 2.1) 
Estimated glomerular filtration rate 
(ml/min/1.73 m2) 
103.6 (92.6, 113.8) 
 
Baseline characteristics of the Northern Sweden study cohort. Continuous variables are presented as 
median (25th, 75th percentile), binary variables as absolute and relative frequencies. Glomerular filtration 
rate was estimated using the CKD-EPI formula with creatinine [29]. NT-proBNP: N-terminal pro B-type 
natriuretic peptide. 
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Table S6. Baseline characteristics of the SHHEC cohort. 
  Study population 
N=15957 
Age (years) 49.8 (43.2, 55.9) 
Sex (male) 8041 (50.4%) 
Body mass index (kg/m2) 25.4 (23.1, 28.1) 
Total serum cholesterol (mmol/l) 6.2 (5.4, 7.1) 
Average daily consumption of alcohol (g) 6.0 (0.0, 18.0) 
Systolic blood pressure (mmHg) 129.0 (118.0, 143.0) 
Heart rate (bpm) Not available. 
Antihypertensive medication No. (%) 1186 (7.4%) 
Smoking No. (%) 6130 (38.4%) 
Prevalent diabetes No. (%) 274 (1.7%) 
Prevalent myocardial infarction No. (%) 518 (3.3%) 
Prevalent stroke No. (%) 155 (1.0%) 
NT-proBNP (pg/mL) 52.2 (28.0, 97.1) 
High-sensitive C-reactive protein (mg/L) 1.4 (0.6, 3.1) 
Estimated glomerular filtration rate (ml/min/1.73 
m2) 
95.9 (84.1, 104.6) 
 
Baseline characteristics of the SHHEC study cohort. Continuous variables are presented as median 
(25th, 75th percentile), binary variables as absolute and relative frequencies. Glomerular filtration rate 
was estimated using the CKD-EPI formula with creatinine [29]. NT-proBNP: N-terminal pro B-type 
natriuretic peptide. 
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Table S7. Association of risk factors and biomarker with incident diseases in females. 
 Disease Hazard ratio 
(95% CI) 
P-Value 
Age (per 5 years increase) 
AF 1.66 (1.55 - 1.79) <0.01 
HF 1.66 (1.56 - 1.77) <0.01 
Body mass index (per 5 kg/m2 
increase) 
AF 1.26 (1.18 - 1.35) <0.01 
HF 1.40 (1.31 - 1.49) <0.01 
Total serum cholesterol (per 1 
mmol/L increase) 
AF 1.02 (0.96 - 1.08) 0.63 
HF 1.02 (0.95 - 1.08) 0.62 
Antihypertensive medication 
AF 1.39 (1.15 - 1.67) <0.01 
HF 1.56 (1.30 - 1.86) <0.01 
Smoking 
AF 1.10 (0.92 - 1.32) 0.29 
HF 2.35 (2.00 - 2.77) <0.01 
Prevalent diabetes 
AF 1.52 (0.77 - 3.02) 0.23 
HF 3.60 (2.41 - 5.37) <0.01 
Prevalent myocardial infarction 
AF 2.25 (1.35 - 3.77) <0.01 
HF 1.68 (1.05 - 2.69) 0.03 
Log10(NT-proBNP) (per 0.3 increase) 
AF 1.71 (1.51 - 1.93) <0.01 
HF 1.44 (1.30 - 1.60) <0.01 
High-sensitive C-reactive protein (per 
5 mg/l increase) 
AF 0.99 (0.88 - 1.12) 0.93 
HF 1.16 (1.11 - 1.21) <0.01 
Estimated Glomerular filtration rate 
(per 20 ml/min/1.73 m2 increase) 
AF 1.00 (0.91 - 1.11) 0.95 
HF 0.92 (0.84 - 1.00) 0.06 
Incident atrial fibrillation during 
follow-up 
   
 HF 5.25 (2.75 - 10.04) <0.01 
Incident heart failure during follow-up 
AF 9.59 (4.73 - 19.44) <0.01 
   
The following variables were also fitted into, but then dropped from the Cox regression model: 
cholesterol-lowering medication, daily consumption of alcohol, systolic blood pressure, heart rate, 
prevalent stroke. In addition, cohort-stratification was adjusted for. After Bonferroni correction to account 
for multiple testing, a p-value threshold of <0.002 was used. Additional interaction terms were added to 
improve model fit: diabetes and age, diabetes and cholesterol, log10(NT-proBNP) and age, log10(NT-
proBNP)  and log10(NT-proBNP), C-reactive protein and age, AF/HF and age, AF/HF and 
antihypertensive medication, log10(NT-proBNP) and prevalent myocardial infarction, AF/HF and 
log10(NT-proBNP), age and time, C-reactive protein and time, Northern Sweden and time, DanMONICA 
and time. P-values and confidence intervals estimated by bootstrapping with 1000 repetitions. AF: atrial 
fibrillation; HF: heart failure; CI: confidence interval; NT-proBNP: N-terminal pro B-type natriuretic 
peptide.  
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Table S8. Association of risk factors and biomarker with incident diseases in males. 
 Disease Hazard ratio 
(95% CI) 
P-Value 
Age (per 5 years increase) 
AF 1.38 (1.32 - 1.45) <0.01 
HF 1.50 (1.43 - 1.57) <0.01 
Body mass index (per 5 kg/m2 
increase) 
AF 1.39 (1.28 - 1.50) <0.01 
HF 1.45 (1.34 - 1.56) <0.01 
Total serum cholesterol (per 1 
mmol/L increase) 
AF 1.01 (0.96 - 1.07) 0.66 
HF 1.13 (1.07 - 1.19) <0.01 
Antihypertensive medication 
AF 1.13 (0.95 - 1.33) 0.16 
HF 1.50 (1.29 - 1.75) <0.01 
Smoking 
AF 1.23 (1.07 - 1.42) <0.01 
HF 1.97 (1.72 - 2.24) <0.01 
Prevalent diabetes 
AF 0.99 (0.60 - 1.63) 0.96 
HF 3.20 (2.31 - 4.44) <0.01 
Prevalent myocardial infarction 
AF 1.43 (1.08 - 1.90) 0.01 
HF 1.87 (1.47 - 2.39) <0.01 
Log10(NT-proBNP) (per 0.3 increase) 
AF 1.50 (1.40 - 1.61) <0.01 
HF 1.48 (1.39 - 1.59) <0.01 
High-sensitive C-reactive protein (per 
5 mgLl increase) 
AF 1.00 (0.92 - 1.08) 0.92 
HF 1.10 (1.04 - 1.16) <0.01 
Estimated Glomerular filtration rate 
(per 20 ml/min/1.73 m2 increase) 
AF 1.16 (1.07 - 1.26) <0.01 
HF 1.07 (1.00 - 1.16) 0.06 
Incident atrial fibrillation during 
follow-up 
   
 HF 7.72 (5.21 - 11.45) <0.01 
Incident heart failure during follow-up 
AF 6.49 (4.20 - 10.02) <0.01 
   
The following variables were also fitted into, but then dropped from the Cox regression model: 
cholesterol-lowering medication, daily consumption of alcohol, systolic blood pressure, heart rate, 
prevalent stroke. In addition, cohort-stratification was adjusted for. After Bonferroni correction to account 
for multiple testing, a p-value threshold of <0.002 was used. Additional interaction terms were added to 
improve model fit: diabetes and age, diabetes and cholesterol, log10(NT-proBNP) and age, log10(NT-
proBNP)  and log10(NT-proBNP), C-reactive protein and age, AF/HF and age, AF/HF and 
antihypertensive medication, log10(NT-proBNP) and prevalent myocardial infarction, AF/HF and 
log10(NT-proBNP), age and time, C-reactive protein and time, Northern Sweden and time, DanMONICA 
and time. P-values and confidence intervals estimated by bootstrapping with 1000 repetitions. AF: atrial 
fibrillation; HF: heart failure; CI: confidence interval; NT-proBNP: N-terminal pro B-type natriuretic 
peptide.  
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Table S9. Multivariable-adjusted hazard ratios for subsequent disease onset of incident atrial 
fibrillation and incident heart failure in females. 
 Hazard ratio 
(95% confidence 
intervals) 
P-value 
Age (per 5 years increase) 1.79 (1.63 - 1.96) <0.01 
Body mass index (per 5 kg/m2 increase) 1.55 (1.41 - 1.71) <0.01 
Total serum cholesterol (per 1 mmol/L increase) 1.03 (0.93 - 1.14) 0.62 
Prevalent diabetes  2.09 (1.38 - 3.17) <0.01 
Log10(NT-proBNP) (per 0.3 increase) 2.11 (1.89 - 2.34) <0.01 
 
The following variables were also fitted into, but then dropped from the Cox regression model: 
cholesterol-lowering medication, daily consumption of alcohol, systolic blood pressure, heart rate, 
antihypertensive medication, smoking status, prevalent myocardial infarction, prevalent stroke, high-
sensitive C-reactive protein, estimated glomerular filtration rate. Adjustment for cohort-stratification was 
implemented. After Bonferroni correction to account for multiple testing, a p-value threshold of <0.0022 
was used. Additional interaction terms were added to improve model fit: log10(NT-proBNP) and time. 
NT-proBNP: N-terminal pro B-type natriuretic peptide.  
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Table S10. Multivariable-adjusted hazard ratios for subsequent disease onset of incident atrial 
fibrillation and incident heart failure in males. 
 Hazard ratio 
(95% confidence 
intervals) 
P-value 
Age (per 5 years increase) 1.52 (1.42 - 1.63) <0.01 
Body mass index (per 5 kg/m2 increase) 1.72 (1.53 - 1.94) <0.01 
Total serum cholesterol (per 1 mmol/L increase) 1.15 (1.05 - 1.25) <0.01 
Prevalent diabetes  1.39 (0.97 - 1.99) 0.07 
Log10(NT-proBNP) (per 0.3 increase) 1.91 (1.78 - 2.05) <0.01 
 
The following variables were also fitted into, but then dropped from the Cox regression model: 
cholesterol-lowering medication, daily consumption of alcohol, systolic blood pressure, heart rate, 
antihypertensive medication, smoking status, prevalent myocardial infarction, prevalent stroke, high-
sensitive C-reactive protein, estimated glomerular filtration rate. Adjustment for cohort-stratification was 
implemented. After Bonferroni correction to account for multiple testing, a p-value threshold of <0.0022 
was used. Additional interaction terms were added to improve model fit: log10(NT-proBNP) and time. 
NT-proBNP: N-terminal pro B-type natriuretic peptide.  
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Table S11. Population-attributable risks for 5-year incidence of atrial fibrillation or heart failure 
for common cardiovascular risk factors and circulating biomarkers. 
 Disease PAR (95% CI) P-Value PAR difference 
(95% CI)  
P-value 
Body mass index 
AF 19.9 (13.5/26.3) <0.01 
 -8.1 (-15.9/0.0) 0.05 
HF  28.0 (22.2/33.6) <0.01 
Total serum cholesterol 
AF  -1.6 (-9.7/7.2) 0.76 
 -5.2 (-15.3/5.7) 0.34 
HF  3.6 (-4.1/11.2) 0.37 
Antihypertensive medication 
AF 7.9 (3.6/12.2) <0.01 
-8.0 (-13.2/-2.7) <0.01 
HF  15.9 (11.9/19.8) <0.01 
Smoking 
AF 3.3 (1.2/5.4) <0.01 
-11.8 (-14.7/-8.9) <0.01 
HF 15.1 (12.7/17.6) <0.01 
Prevalent diabetes 
AF  1.4 (-3.5/5.6) 0.66 
 -11.6 (-17.2/-6.7) <0.01 
HF 13.0 (10.4/15.6) <0.01 
 
P-values and confidence intervals estimated by bootstrapping. For the calculation of PARs, continuous 
variables were categorized as follows: body mass index using three categories <25 kg/m2, 25 to <30 
kg/m2, ≥30 kg/m2 and total cholesterol using two categories based on the cutoff value 5.2 mmol/L. The 
category containing the lowest values was taken as reference level during the PAR calculation. PAR: 
population-attributable risks; CI: confidence interval; AF: atrial fibrillation; HF: heart failure.  
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